Thiopurine S-methyltransferase alleles, TPMT*2, *3B, and *3C, and genotype frequencies in an indian population

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 127-

  Murugesan, Raju ^a   Saadi, Abdul Vahab ^a   Patra, Satyajit ^a   Rao, Rekha ^a   Rao, Jyothi ^a   Rai, Padmalatha ^a   Gopinath, P M ^a   Satyamoorthy, Kapaettu ^a  

^a MANIPAL UNIVERSITY   (India)

Author keywords

Azathioprine; Genetic testing; Indian population; Mercaptopurine; Pharmacogenetics; Polymorphisms; Thiopurine s methyltransferase

Indexed keywords

GENOMIC DNA; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; DNA ISOLATION; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENE MAPPING; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INDIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77955751800     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000021     Document Type: Article

References (41)

1. Remy CN: Metabolism of thiopyrimidines and thiopurines. S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J biol chem 238: 1078-1084, 1963.
2. Tidd DM and Paterson AR: A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer res 34: 738-746, 1974.
3. Lennard L, Van Loon JA, Lilleyman JS and Weinshilboum RM: Thiopurine pharmacogenetics in leukemia: correlation of eryth-rocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin pharmacol ther 41: 18-25, 1987.
4. Krynetski EY and Evans WE: Drug methylation in cancer therapy: lessons from the tpmt polymorphism. Oncogene 22: 7403-7413, 2003.
5. Woodson LC, Dunnette JH and Weinshilboum RM: pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J pharmacol exp ther 222: 174-181, 1982.
6. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV and Evans WE: Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6: 279-290, 1996.
7. Snow JL and Gibson LE: The role of genetic variation in thiopu-rine methyltransferase activity and the effcacy and/or side effects of azathioprine therapy in dermatologic patients. Arch dermatol 131: 193-197, 1995.
8. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, Wieben ED and Weinshilboum RM: Thiopurine methyltransferase pharmacogenetics. cloning of human liver cdna and a processed pseudogene on human chromosome 18q21.1. Drug metab dispos 23: 398-405, 1995.
9. Hon YY, Fessing MY, Pui C-H, Relling MV, Krynetski EY and Evans WE: polymorphism of the thiopurine S-methyltransferase gene in african-americans. Hum mol Genet 8: 371-376, 1999.
10. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY and Relling MV: Preponderance of thiopurine S-methyltransferase defciency and heterozygosity among patients intolerant to mercap-topurine or azathioprine. J clin oncol 19: 2293-2301, 2001.
11. LINDQVIST M, HAGLUND S, ALMER S, PETERSON C, TAIPALENSU J, HERTERVIG E, LYRENÄS E and SÖDERKVIST P: Identifcation of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 14: 261-265, 2004.
12. KRYNETSKI EY, SCHUETZ JD, GALPIN AJ, PUI C-H, RELLING MV and EVANS WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc natl acad Sci USA 92: 949-953, 1995.
13. TAI HL, KRYNETSKI EY, YATES CR, LOENNECHEN T, FESSING MY, KRYNETSKAIA NF and EVANS WE: Thiopurine S-methyltransferase defciency: two nucleotide transitions defne the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am j hum Genet 58: 694-702, 1996.
14. OTTERNESS D, SZUMLANSKI C, LENNARD L, KLEMETSDAL B, AARBAKKE J, PARK-HAH JO, IVEN H, SCHMIEGELOW K, BRANUM E, OBRIEN J and WEINSHILBOUM R: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin pharmacol ther 62: 60-73, 1997.
15. OTTERNESS DM, SZUMLANSKI CL, WOOD TC and WEINSHILBOUM RM: Human thiopurine methyltransferase pharmacogenetics. kindred with a terminal exon splice junction mutation that results in loss of activity. J clin invest 101: 1036-1044, 1998.
16. MANIATIS T, FRITSCH EF and SAMBROOK J: Analysis and cloning of eukaryotic genomic dna. in: molecular cloning. 2nd edition: a laboratory manual. Cold Spring harbor, new york, pp 9.16-9.23, 1989.
17. LENNARD L, LILLEYMAN JS, VAN LOON J and WEINSHILBOUM RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229, 1990.
18. WEINSHILBOUM R: Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug metab dispos 29: 601-605, 2001.
19. COULTHARD SA, HOGARTH LA, LITTLE M, MATHESON EC, REDFERN CPF, MINTO L and HALL AG: The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol pharmacol 62: 102-109, 2002.
20. YATES CR, KRYNETSKI EY, LOENNECHEN T, FESSING MY, TAI HL, PUI CH, RELLING MV and EVANS WE: Molecular diagnosis of thiopurine S-methyltransferase defciency: genetic basis for azathioprine and mercaptopurine intolerance. Ann intern med 126: 608-614, 1997.
21. BLACK AJ, MCLEOD HL, CAPELL HA, POWRIE RH, MATOWE LK, PRITCHARD SC, COLLIE-DUGUID ESR and REID RM: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann intern med 129: 716-718, 1998.
22. KHAM SK, TAN PL, TAY AH, HENG CK, YEOH AE and QUAH TC: Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia. J pediatr hematol oncol 24: 353-359, 2002.
23. AMEYAW MM, COLLIEDUGUID ES, POWRIE RH, OFORI-ADJEI D and MCLEOD HL: thiopurine methyltransferase alleles in british and Ghanaian populations. Hum mol Genet 8: 367-370, 1999.
24. LEIPOLD G, SCHÜTZ E, HAAS JP and OELLERICH M: Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile hla-b27-associated spondylarthritis. Arthritis rheum 40: 1896-1898, 1997.
25. LARÓVERE LE, DE KREMER RD, LAMBOOY LH and DE ABREU RA: Genetic polymorphism of thiopurine S-methyltransferase in argentina. Ann clin biochem 40: 388-393, 2003.
26. REIS M, SANTORO A and SUAREZKURTZ G: Thiopurine methyltrans-ferase phenotypes and genotypes in brazilians. Pharmacogenetics 13: 371-373, 2003.
27. MCLEOD HL, PRITCHARD SC, GITHANG A J, INDALO A, AMEYAW MM, POWRIE RH, BOOTH L and COLLIEDUGUID ES: Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specifcity in Caucasian and Kenyan individuals. Pharmacogenetics 9: 773-776, 1999.
28. COLLIEDUGUID ES, PRITCHARD SC, POWRIE RH, SLUDDEN J, COLLIER DA, LI T and MCLEOD HL: The frequency and distribution of thiopurine methyltransferase alleles in caucasian and asian populations. Pharmacogenetics 9: 37-42, 1999.
29. ISAZA C, HENAO J, LÓPEZ AM and CACABELOS R: Allelic variants of the thiopurine methyltransferase (TPMT) gene in the colombian population. Methods Find exp clin pharmacol 25: 423-429, 2003.
30. HAMDY SI, HIRATSUKA M, NARAHARA K, ENDO N, ELENANY M, MOURSI N, AHMED MS-E and Mizugaki M: Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the egyptian population. Br j clin pharmacol 55: 560-569, 2003.
31. GANIEREMONTEIL C, MEDARD Y, LEJUS C, BRUNEAU B, PINEAU A, FENNETEAU O, BOURIN M and JACQZAIGRAIN E: Phenotype and genotype for thiopurine methyltransferase activity in the French caucasian population: impact of age. Eur j clin pharmacol 60: 89-96, 2004.
32. ROSSI AM, BIANCHI M, GUARNIERI C, BARALE R and PACIFCI GM: Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy italian subjects. Eur j clin pharmacol 57: 51-54, 2001.
33. HIRATSUKA M, INOUE T, OMORI F, AGATSUMA Y, KISHIKAWA Y and MIZUGAKI M: Detection assay of rare variants of the thiopurine methyltransferase gene by pcr-rFlp using a mismatch primer in a japanese population. Biol pharm bull 23: 1090-1093, 2000.
34. WEI H, ZHOU S, LI C, ZHANG J, WU J and HUANG M: Phenotyping and genotyping studies of thiopurine S-methyltransferase in kazaks. Pharm res 22: 1762-1766, 2005.
35. LOENNECHEN T, UTSI E, HARTZ I, LYSAA R, KILDALSEN H and AARBAKKE J: Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern norway. Clin pharmacol ther 70: 183-188, 2001.
36. ALVES S, PRATA MJ, FERREIRA F and AMORIM A: Thiopurine methyl-transferase pharmacogenetics: alternative molecular diagnosis and preliminary data from northern portugal. Pharmacogenetics 9: 257-261, 1999.
37. KURZAWSKI M, GAWRONSKASZKLARZ B and DROZDZIK M: Frequency distribution of thiopurine S-methyltransferase alleles in a polish population. Ther drug monit 26: 541-545, 2004.
38. CHANG JG, LEE LS, CHEN CM, SHIH MC, WU MC, TSAI FJ and LIANG DC: Molecular analysis of thiopurine S-methyltransferase alleles in South-east asian populations. Pharmacogenetics 12: 191-195, 2002.
39. HAGLUND S, LINDQVIST M, ALMER S, PETERSON C and TAIPALENSUU J: Pyrosequencing of tpmt alleles in a general Swedish population and in patients with infammatory bowel disease. Clin Chem 50: 288-295, 2004.
40. SRIMARTPIROM S, TASSANEEYAKUL W, KUKONGVIRIYAPAN V and TASSANEEYAKUL W: Thiopurine S-methyltransferase genetic polymorphism in the thai population. Br j clin pharmacol 58: 66-70, 2004.
41. VESELL ES: Therapeutic lessons from pharmacogenetics. Ann intern med 126: 653-655, 1997.